Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer multidrug resistance (MDR) is a complex phenotype involving multiple molecular and cellular changes.
• Drug efflux transporters, such as P-glycoprotein ABCB1, are crucial but insufficient alone for MDR.
• Sphingolipids, vital for cell membranes and protein function, are altered in cancer and influence transporter activity.

Purpose of the Study:

• To review the roles of sphingolipid alterations and ABCB1 in the development of cancer MDR.
• To postulate a model where early sphingomyelin increases recruit ABCB1, establishing partial MDR.
• To discuss how subsequent glycosphingolipid changes and vesicular ABCB1 contribute to complete MDR.

Main Methods:

• Literature review focusing on sphingolipid metabolism and ABCB1 function in cancer.
• Analysis of independent and interdependent roles of these factors in MDR development.
• Integration of findings to propose a mechanistic model of MDR conferment.

Main Results:

• Increased sphingomyelin content early in cancer can recruit and functionalize plasma membrane ABCB1, conferring partial MDR.
• Further alterations in glycosphingolipids and the emergence of intracellular vesicular ABCB1 complete the MDR phenotype.
• Sphingolipid alterations and ABCB1 upregulation act both independently and interdependently during oncogenesis and MDR development.

Conclusions:

• Sphingolipid metabolism is a critical, early determinant of cancer MDR.
• Targeting sphingolipid pathways alongside ABCB1 may offer novel therapeutic strategies against MDR cancer.
• Understanding these molecular interplay is essential for overcoming drug resistance in oncology.